Nexstim Plc · OMXHEX:NXTMH
Nexstim — H1 2024 Earnings Presentation
10 slides from Nexstim's earnings presentation, Aug 16, 2024
Slide 1: Nexstim - Personalized Brain Diagnostics and Therapy
Nexstim - Personalized Brain Diagnostics and Therapy Mikko Karvinen| CEO| Nexstim Plc Joonas Juokslahti| CFO| Nexstim Plc H1 2024 Financial Results Webinar, 16 August 2024
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj as, a promise or representation as to future performance. The Company does not undertake any (“Nexstim” or the “Company”). In connection with any presentation or review of this document, oblig
Slide 3: Nexstim Story
Nexstim Story Nexstim is a Finnish, globally operating growth-oriented medical technology company. MISSION VISION VALUES • We enable personalized and • With our technological know-how • Science and clinical evidence effective therapies and and superior services, • Financial success diagnostics for c
Slide 4: Megatrends that Support our Growth
Megatrends that Support our Growth Nexstim’s unique proprietary neuronavigated TMS-technology for both diagnostic and therapy applications. 1 2 3 Technological Healthcare cost Aging population development in pressures healthcare • Population aging and a • Technological • The need for more significan
Slide 5: Our Business and Products
Our Business and Products Commercial Business System Application Europe United States Status NBS 5 Diagnostics (Navigated Over 230 Pre-surgical FDA CE marked Business Brain systems sold mapping approved Stimulation) FDA approved NBT® & NBS 6 Over 90 Depression CE marked with existing Therapy (Naviga
Slide 6: Business and Financial Summary H1 2024
Nexstim Business and Financial Summary H1 2024 • Nexstim continued to grow and improved its profitability • System sales were EUR 1.2M (2023 H1: EUR 1.1M), • In line with our main strategic objective, we have continued to with an increase of 11.4%. Recurring net sales were focus on profitable net sa
Slide 7: H1 2024 Key Financials
H1 2024 Key Financials Net Sales 3.2M€ +27% 1–6/2024 1–6/2023 1–12/2023 EUR in thousands 6 months 6 months Change-% 12 months • Diagnostic 1.6M€ +16% • Therapy 1.6M€ +39% • System sales 1.2M€ +11% Net Sales 3,176.9 2,503.7 26.9% 7,426.3 • Recurring 1.9M€ +39% Gross margin 2,603.0 1,992.7 30.6% 5,645
Slide 8: Key Strategic Objectives 2024
Nexstim Key Strategic Objectives 2024 1 2 3 Profitable Growth Technology Leadership Strategic Partnerships To increase comparable Launch of the new NBS 6 Expanding Nexstim's net sales and improve diagnostics product, network of partners and operating result for the enabling easy-to-use clinics, prim
Slide 9: NBS 6 – future of the Nexstim system
NBS 6 – future of the Nexstim system Developing and lauching a new product generation is an essential part of Nexstim’s work during the 2020-2024 strategy period • The NBS 6 is a new combined system that has been built 1 on Nexstim’s unique, clinically established technology. • The modular product d
Slide 10: Thank you!
Thank you! @NexstimOyj Follow us on social media: @Nexstim @NexstimTMS Nexstim Oyj Nexstim Plc Public Presentation 10